KORTHOS / ECOSYSTEM / PRODUCT

LIBERTY Endovascular Robotic System

About

About LIBERTY Endovascular Robotic System

LIBERTY is a compact, single-use robotic system that lets a physician remotely manipulate guidewires, catheters and guide catheters during peripheral endovascular procedures. AccuGrip controls provide fine advancement and rotation from a position away from the radiation source while preserving use of conventional compatible interventional devices.

The disposable architecture avoids permanent capital equipment and extensive room installation, with setup designed to take less than five minutes. Microbot Medical supplies a starter configuration, training and procedure support around the cleared system. Its current FDA indication covers peripheral endovascular navigation and should not be extended to coronary or neurovascular procedures without separate authorisation.

Timeline

  • Microbot Medical adds Sanmina manufacturing capacity for LIBERTY

    2026-06-30 - Production Milestone - Microbot framed the Sanmina agreement as a second manufacturing site and capacity expansion. LIBERTY is an FDA-cleared, single-use robotic system for remote endovascular procedures.

    Source
  • Microbot Medical expands LIBERTY commercial footprint to seven Eastern U.S. states

    2026-06-23 - Market Signal - Microbot said the system spans multiple hospitals and specialty centers serving Pennsylvania and New Jersey. The company said LIBERTY now has accounts across seven Eastern U.S. states.

    Source
  • Microbot Medical adds first Michigan LIBERTY healthcare-system customer

    2026-06-09 - Market Signal - Microbot Medical announced the first Michigan healthcare-system adoption of its LIBERTY endovascular robotic system. The company described the customer as one of Michigan’s largest healthcare systems. The adoption followed North Carolina expansion and supported LIBERTY’s Midwest commercial rollout.

    Source
  • Microbot Medical starts U.S. limited market release for LIBERTY

    2025-11-05 - Product Launch - LIBERTY became commercially available in the U.S. through selected high-procedure-volume regions. The company said the launch followed commercial-team hiring and a third-party logistics partnership. The product gives The company a concrete offering for warehouse automation and material-handling workflows.

    Source
  • Microbot Medical receives FDA clearance for LIBERTY endovascular robot

    2025-09-08 - Regulatory - Microbot Medical received FDA 510(k) clearance for the LIBERTY endovascular robotic system. The clearance moved LIBERTY from development into a regulated commercial pathway for endovascular procedures. The event anchors Microbot as a surgical robotics pure play with a cleared robotic system.

    Source

Context

Comparable Systems